





Epidemiología de los Linfomas T en LatinoAmérica



Characteristics	All patients ^a , No. (%)	GELL ^b , No. (%)	Brazilian TCP, No. (%)	ITCP-LATAM ^c , No. (%)	P-value
No. of patients	2110	988	593	529	
Study period, years	1975 - 2023	1975 - 2023	2015 - 2023	2006 - 2023	
Age at diagnosis in years, median (range)	54 (18 - 95)	55 (18 - 95)	52 (18 - 92)	53 (18 - 86)	0.116
Males	1073 (59)	585 (59)	349 (59)	139 (59)	0.987
Missing	295	1	0	294	


Epidemiology of PTCL in LATAM






Epidemiology of PTCL by Registry



GELL
(n = 1016)









Brazilian TČP
(n = 593)



ITCP-LATAM
(n = 529)




Epidemiology of PTCL by Country



■ PTCL-NOS ■ ATL ■ ENKTL
 ■ ALK- ALCL ■ ALK+ ALCL ■ AITL
 ■ Others ■ Mature T-cell NOS




Overall Survival of PTCL



3-year OS (95% CI)	
ALK+ ALCL	77 (66-90)
ALK- ALCL	53 (44-64)
PTCL-NOS	38 (33-44)
ENKTL	49 (42-56)
AITL	37 (26-52)
ATL	23 (18-30)
Others	35 (20-63)

No. at risk	0	12	24	36
ALK+ ALCL	51	37	29	25
ALK- ALCL	135	72	42	35
ENKTL	225	113	83	67
PTCL-NOS	488	206	122	86
AITL	85	40	19	10
Others	31	9	7	4
ATL	323	95	48	33



3-year PFS (95% CI)	
ALK+ ALCL	73 (62-87)
ALK- ALCL	36 (28-47)
PTCL-NOS	27 (22-32)
ENKTL	45 (39-53)
AITL	25 (16-39)
ATL	16 (12-21)
Others	18 (7-41)

No. at risk	0	12	24	36
ALK+ ALCL	52	33	26	22
ALK- ALCL	135	58	33	26
ENKTL	226	102	79	65
PTCL-NOS	488	172	91	66
AITL	85	26	11	4
Others	33	7	5	4
ATL	323	69	41	26

REAL-WORLD DATA FOR THE TREATMENT OF NEWLY DIAGNOSED PTCL

	All N = 698	USA* N = 311	Australia N = 69	Brazil N = 120	South Korea N = 123	South Africa N = 24	Saudi Arabia N = 13	Japan N = 38
Treatment								
CHOP-based	37%	35%	48%	20%	62%	25%	23%	18%
CHOEP-based	28%	31%	26%	50%	3%	71%	23%	0
EPOCH-based	5%	10%	2%	< 1%	2%	0	0	3%
CHP + BV	2%	4%	0	< 1%	0	0	23%	0
Alemtuzumab	1%	2%	0	0	0	0	8%	0
Other	27%	20%	25%	28%	33%	4%	25%	79%

Globally, most patients receive CHOP- or CHOEP- based combination chemotherapy for newly diagnosed PTCL – Whats the SOC?

Boussi LS, et al. *Blood*. 2022;140:10976-10978.

*Based on the COMPLETE Registry enrolling between 2010 to 2014


Con el Aval:






First-line therapy regimens by Registry


GELL
(n = 731)



Brazilian TCP
(n = 548)



ITCP-LATAM
(n = 371)




- Doxorubicin containing
- Doxorubicin+Etoposide containing
- Etoposide containing
- Other multiagent chemotherapy
- Single agent chemotherapy



Therapy responses


CR PR SD PD





Overall Survival of PTCL by Regimen

PTCL-NOS



No. at risk

CHOEP/EPOCH	181	85	51	38
CHOP	179	91	52	34



¡GRACIAS!